曲美他嗪治疗缺血性心肌病心力衰竭的疗效观察  

Observation on efficacy of trimetazidine in the treatment of ischemic cardiomyopathy and heart failure

作　　者：刘晓晨 LIU Xiao-chen(Panjin Central Hospital,Panjin 124010,China)

机构地区：[1]盘锦市中心医院,124010

出　　处：《中国现代药物应用》2022年第13期95-97,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究曲美他嗪治疗缺血性心肌病心力衰竭的临床疗效。方法80例缺血性心肌病心力衰竭患者,按照入院先后顺序分为对照组与实验组,各40例。对照组采用常规治疗方式,实验组在对照组治疗基础上采用曲美他嗪片治疗。对比两组治疗前后各项心功能指标[左室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)以及QT间期离散度(QTd)]、治疗效果及治疗过程中不良反应发生情况。结果治疗90 d后,两组LVEF、LVESD、LVEDD及QTd均优于本组治疗前,且实验组LVEF(55.69±6.24)%、LVESD(43.27±3.11)mm、LVEDD(51.27±3.26)mm及QTd(59.38±6.22)ms均优于对照组的(49.63±5.17)%、(48.74±4.52)mm、(57.28±4.35)mm及(65.73±5.11)ms,差异均有统计学意义(P<0.05)。实验组治疗总有效率为95.00%,显著高于对照组的77.50%,差异有统计学意义(P<0.05)。实验组不良反应发生率为7.50%,显著低于对照组的27.50%,差异有统计学意义(P<0.05)。结论对缺血性心肌病心力衰竭患者实施曲美他嗪治疗的效果较好,患者的心功能指标得到明显改善,不良反应发生情况更少,值得推广。Objective To investigate the clinical efficacy of trimetazidine in the treatment of ischemic cardiomyopathy and heart failure.Methods A total of 80 patients with ischemic cardiomyopathy and heart failure were divided into control group and experimental group according to the order of admission,with 40 cases in each group.The control group was treated with conventional treatment,and the experimental group was treated with trimetazidine tablets based on the treatment of the control group.Both groups were compared in terms of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)and QT interval dispersion(QTd)]before and after treatment,therapeutic effects,and occurrence of adverse reactions during treatment.Results After 90 d of treatment,the levels of LVEF,LVESD,LVEDD and QTd in the two groups were better than those before treatment in this group;the LVEF(55.69±6.24)%,LVESD(43.27±3.11)mm,LVEDD(51.27±3.26)mm and QTd(59.38±6.22)ms of the experimental group were all better than(49.63±5.17)%,(48.74±4.52)mm,(57.28±4.35)mm and(65.73±5.11)ms of the control group;all the differences were statistically significant(P<0.05).The total effective rate of treatment in the experimental group was 95.00%,which was significantly higher than 77.50% in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was 7.50%,which was significantly lower than 27.50%in the control group,and the difference was statistically significant(P<0.05).Conclusion Trimetazidine has good effect on patients with ischemic cardiomyopathy and heart failure,and can obviously improve the cardiac function indicators of patients with less adverse reactions,which is worthy of promotion.

关 键 词：曲美他嗪 缺血性心肌病心力衰竭 治疗效果 

分 类 号：R541.6[医药卫生—心血管疾病] R542.2[医药卫生—内科学]